This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > BCX7353 for prevention of acute attacks of angioedema in hereditary angioedema

< Back

BCX7353 for prevention of acute attacks of angioedema in hereditary angioedema


Immunology and Allergy

April 2019

BCX7353 is in clinical development for routine prevention of angioedema attacks in patients with hereditary angioedema (HAE). HAE is a rare genetic disorder of blood vessels characterised by recurrent episodes of severe swelling (angioedema) below the skin which often affect the face, throat, stomach, genitals, hands or feet, causing discomfort and pain. HAE may be life threatening when the swelling occurs in the throat as it can obstruct the airways and impede breathing. HAE has no known cure and the goal of treatment is to minimise the burden of illness on patients and enable them to lead normal lives. Long-term preventive treatments are used routinely to reduce the need for treatment of acute attacks. Currently available treatments are given by injection.
BCX7353 is an oral treatment that works by blocking the activity the specific pathway that becomes overactive in patients with angioedema. By blocking this pathway, BCX7353 is expected to reduce the number of angioedema attacks. Early studies of BCX7353 has shown that it helped to prevent swelling and inflammation in HAE. In addition, BCX7353 has the distinct advantage over current treatment of being administered orally, making it easier to use for routine prevention of HAE attacks.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts